Rep. Rick Larsen Purchases Shares of Abbott Laboratories (NYSE:ABT)

Representative Rick Larsen (D-Washington) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on October 6th. The trade occurred in the Representative’s “RICHARD R LARSEN IRA” account.

Representative Rick Larsen also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Zoetis (NYSE:ZTS) on 10/6/2025.
• Purchased $1,001 – $15,000 in shares of Walmart (NYSE:WMT) on 10/6/2025.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 10/6/2025.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 10/6/2025.
• Sold $1,001 – $15,000 in shares of Old Dominion Freight Line (NASDAQ:ODFL) on 10/6/2025.

Abbott Laboratories Stock Up 0.8%

ABT stock opened at $128.69 on Friday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a market capitalization of $223.98 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 2.42 and a beta of 0.69. The firm’s 50-day moving average is $132.38 and its two-hundred day moving average is $131.54. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same period in the previous year, the firm earned $1.21 EPS. Abbott Laboratories’s revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.46% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Barclays boosted their price target on shares of Abbott Laboratories from $159.00 to $162.00 and gave the stock an “overweight” rating in a research report on Friday. The Goldman Sachs Group boosted their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Evercore ISI lowered their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research note on Wednesday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a research note on Thursday. Finally, Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $147.61.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. IMG Wealth Management Inc. increased its position in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 167 shares in the last quarter. Hughes Financial Services LLC purchased a new position in shares of Abbott Laboratories in the first quarter worth approximately $27,000. Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the first quarter worth approximately $28,000. Elequin Capital LP purchased a new position in shares of Abbott Laboratories in the first quarter worth approximately $30,000. Finally, JCIC Asset Management Inc. purchased a new position in shares of Abbott Laboratories in the first quarter worth approximately $32,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

About Representative Larsen

Rick Larsen (Democratic Party) is a member of the U.S. House, representing Washington’s 2nd Congressional District. He assumed office on January 3, 2001. His current term ends on January 3, 2027.

Larsen (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 2nd Congressional District. He declared candidacy for the 2026 election.

Since at least 2011, Larsen has been assigned to the Committee on Armed Services and the Committee on Transportation and Infrastructure.

Larsen’s first position as an elected official was in 1998 as a member of the Snohomish County Council.

Larsen earned his bachelor’s degree from Pacific Lutheran University. After earning his master’s degree in public affairs from the University of Minnesota, Larsen worked as the director of public affairs for the Washington State Dental Association and then as an economic development official with the Port of Everett. He went on to serve on the Snohomish County Council before seeking election to the U.S. House.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.